AR091218A1 - Agente terapeutico o agente profilactico para los trastornos cognitivos - Google Patents
Agente terapeutico o agente profilactico para los trastornos cognitivosInfo
- Publication number
- AR091218A1 AR091218A1 ARP130101907A AR091218A1 AR 091218 A1 AR091218 A1 AR 091218A1 AR P130101907 A ARP130101907 A AR P130101907A AR 091218 A1 AR091218 A1 AR 091218A1
- Authority
- AR
- Argentina
- Prior art keywords
- agent
- cognitive disorders
- amino acid
- profilactic
- therapeutic agent
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 title abstract 2
- 208000010877 cognitive disease Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 229940124597 therapeutic agent Drugs 0.000 title abstract 2
- 125000000539 amino acid group Chemical group 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012124336 | 2012-05-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR091218A1 true AR091218A1 (es) | 2015-01-21 |
Family
ID=49673425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130101907 AR091218A1 (es) | 2012-05-31 | 2013-05-30 | Agente terapeutico o agente profilactico para los trastornos cognitivos |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US20150183854A1 (enExample) |
| EP (2) | EP2857039B1 (enExample) |
| JP (3) | JP5971659B2 (enExample) |
| KR (2) | KR102208283B1 (enExample) |
| CN (1) | CN104602708B (enExample) |
| AR (1) | AR091218A1 (enExample) |
| AU (2) | AU2013268364B2 (enExample) |
| BR (1) | BR112014029566A2 (enExample) |
| CA (1) | CA2875205C (enExample) |
| CY (1) | CY1122530T1 (enExample) |
| DK (1) | DK2857039T3 (enExample) |
| ES (2) | ES2973070T3 (enExample) |
| HR (1) | HRP20192267T1 (enExample) |
| HU (1) | HUE046919T2 (enExample) |
| IL (1) | IL235899B (enExample) |
| LT (1) | LT2857039T (enExample) |
| ME (1) | ME03587B (enExample) |
| MX (1) | MX361128B (enExample) |
| MY (1) | MY172458A (enExample) |
| NZ (1) | NZ630536A (enExample) |
| PH (1) | PH12014502669B1 (enExample) |
| PL (1) | PL2857039T3 (enExample) |
| PT (1) | PT2857039T (enExample) |
| RS (1) | RS59802B1 (enExample) |
| RU (1) | RU2657438C2 (enExample) |
| SG (2) | SG11201407878VA (enExample) |
| SI (1) | SI2857039T1 (enExample) |
| TW (2) | TWI777183B (enExample) |
| WO (1) | WO2013180238A1 (enExample) |
| ZA (1) | ZA201409186B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2826286C (en) | 2011-01-31 | 2021-09-21 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| EP2709728B1 (en) * | 2011-05-20 | 2019-01-23 | Oligomerix, Inc. | Tau protease methods of use |
| MY172458A (en) * | 2012-05-31 | 2019-11-26 | Teijin Pharma Ltd | Therapeutic agent or prophylactic agent for dementia |
| MY171473A (en) | 2012-07-03 | 2019-10-15 | Univ Washington | Antibodies to tau |
| TW202136296A (zh) | 2014-06-27 | 2021-10-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
| US20190224339A1 (en) * | 2016-04-29 | 2019-07-25 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| JP6785372B2 (ja) * | 2016-09-30 | 2020-11-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 多重特異性分子の機能分析のためのｓｐｒに基づく二重結合アッセイ |
| MA47499A (fr) | 2017-02-17 | 2019-12-25 | Denali Therapeutics Inc | Anticorps anti-tau et leurs procédés d'utilisation |
| JOP20180014A1 (ar) * | 2017-02-27 | 2019-01-30 | Teijin Pharma Ltd | جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه |
| CN110691794B (zh) | 2017-05-30 | 2023-10-27 | 帝人制药株式会社 | 抗igf-i受体抗体 |
| GEP20227406B (en) | 2017-10-02 | 2022-08-25 | Merck Sharp & Dohme | Chromane monobactam compounds for the treatment of bacterial infections |
| WO2019077500A1 (en) | 2017-10-16 | 2019-04-25 | Eisai R&D Management Co., Ltd. | ANTI-WATER ANTIBODIES AND USES THEREOF |
| JP7504026B2 (ja) | 2018-04-06 | 2024-06-21 | 帝人ファーマ株式会社 | Ｓｐｎｓ２中和抗体 |
| JP7340794B2 (ja) * | 2018-07-04 | 2023-09-08 | 学校法人 愛知医科大学 | タウのスプライシングを制御するアンチセンスオリゴヌクレオチド及びその用途 |
| CN110028583B (zh) * | 2019-05-07 | 2020-09-11 | 温州医科大学 | 抗Tau抗体及其在治疗阿尔茨海默病、创伤性脑损伤中的应用 |
| JP7429404B2 (ja) * | 2019-08-06 | 2024-02-08 | 慶應義塾 | タウ関連疾患モデルの製造方法 |
| JP7718270B2 (ja) | 2019-09-30 | 2025-08-05 | ニプロ株式会社 | 血液試料を検体とするタウタンパク質検出方法 |
| EP4121071A4 (en) * | 2020-03-19 | 2024-07-24 | Vascular Biosciences | PEPTIDE CAR FOR IMPROVED CORONAVIRUS SURVIVAL |
| BR112022026575A2 (pt) | 2020-06-25 | 2023-01-17 | Merck Sharp & Dohme Llc | Anticorpos de alta afinidade que alvejam tau fosforilado em serina 413 |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| AU2023342086A1 (en) | 2022-09-15 | 2025-03-13 | Voyager Therapeutics, Inc. | Tau binding compounds |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS587390B2 (ja) | 1975-03-11 | 1983-02-09 | ツキシマキカイ カブシキガイシヤ | ア−クヨウセツホウホウ |
| JP3587390B2 (ja) | 1994-03-17 | 2004-11-10 | タカラバイオ株式会社 | リン酸化アミノ酸誘導体及びリン酸化ペプチド合成方法 |
| US20020086009A1 (en) * | 1996-03-13 | 2002-07-04 | Koichi Ishiguro | Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same |
| US20080199471A1 (en) * | 2002-03-01 | 2008-08-21 | Bernett Matthew J | Optimized cd40 antibodies and methods of using the same |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| US20070280935A1 (en) * | 2006-04-07 | 2007-12-06 | Bernd Bohrmann | Antibody that recognizes phosphorylated peptides |
| EP2028932A4 (en) * | 2006-06-16 | 2011-10-12 | Vitruvean Llc | TAU AND AMYLOID FOREIGNER FRAGMENT EXPRESSING TRANSGENIC FLY |
| UA107571C2 (xx) * | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| US8748386B2 (en) * | 2009-06-10 | 2014-06-10 | New York University | Immunological targeting of pathological Tau proteins |
| CA2826286C (en) * | 2011-01-31 | 2021-09-21 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| TR201102696U (tr) * | 2011-05-27 | 2011-06-21 | Turhal Sal�H | Bağlantısız hareketli ürün reklam standı. |
| MY172458A (en) * | 2012-05-31 | 2019-11-26 | Teijin Pharma Ltd | Therapeutic agent or prophylactic agent for dementia |
| JOP20180014A1 (ar) * | 2017-02-27 | 2019-01-30 | Teijin Pharma Ltd | جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه |
-
2013
- 2013-05-30 MY MYPI2014703534A patent/MY172458A/en unknown
- 2013-05-30 RS RS20191640A patent/RS59802B1/sr unknown
- 2013-05-30 SI SI201331636T patent/SI2857039T1/sl unknown
- 2013-05-30 JP JP2014518734A patent/JP5971659B2/ja active Active
- 2013-05-30 EP EP13797290.7A patent/EP2857039B1/en active Active
- 2013-05-30 HU HUE13797290A patent/HUE046919T2/hu unknown
- 2013-05-30 ES ES19207405T patent/ES2973070T3/es active Active
- 2013-05-30 KR KR1020207007010A patent/KR102208283B1/ko active Active
- 2013-05-30 CA CA2875205A patent/CA2875205C/en active Active
- 2013-05-30 TW TW109121902A patent/TWI777183B/zh active
- 2013-05-30 US US14/403,803 patent/US20150183854A1/en not_active Abandoned
- 2013-05-30 WO PCT/JP2013/065090 patent/WO2013180238A1/ja not_active Ceased
- 2013-05-30 NZ NZ630536A patent/NZ630536A/en unknown
- 2013-05-30 SG SG11201407878VA patent/SG11201407878VA/en unknown
- 2013-05-30 CN CN201380040658.9A patent/CN104602708B/zh active Active
- 2013-05-30 ME MEP-2019-341A patent/ME03587B/me unknown
- 2013-05-30 BR BR112014029566A patent/BR112014029566A2/pt not_active Application Discontinuation
- 2013-05-30 AU AU2013268364A patent/AU2013268364B2/en active Active
- 2013-05-30 SG SG10201805410XA patent/SG10201805410XA/en unknown
- 2013-05-30 HR HRP20192267TT patent/HRP20192267T1/hr unknown
- 2013-05-30 AR ARP130101907 patent/AR091218A1/es active IP Right Grant
- 2013-05-30 MX MX2014014187A patent/MX361128B/es active IP Right Grant
- 2013-05-30 EP EP19207405.2A patent/EP3662931B1/en active Active
- 2013-05-30 LT LTEP13797290.7T patent/LT2857039T/lt unknown
- 2013-05-30 ES ES13797290T patent/ES2763361T3/es active Active
- 2013-05-30 DK DK13797290.7T patent/DK2857039T3/da active
- 2013-05-30 TW TW102119176A patent/TWI700296B/zh active
- 2013-05-30 RU RU2014153099A patent/RU2657438C2/ru active
- 2013-05-30 PL PL13797290T patent/PL2857039T3/pl unknown
- 2013-05-30 PT PT137972907T patent/PT2857039T/pt unknown
- 2013-05-30 KR KR1020147035417A patent/KR102133610B1/ko active Active
-
2014
- 2014-11-25 IL IL235899A patent/IL235899B/en active IP Right Grant
- 2014-11-28 PH PH12014502669A patent/PH12014502669B1/en unknown
- 2014-12-12 ZA ZA2014/09186A patent/ZA201409186B/en unknown
-
2016
- 2016-05-09 JP JP2016094112A patent/JP6406678B2/ja active Active
-
2018
- 2018-01-18 AU AU2018200413A patent/AU2018200413B2/en active Active
- 2018-03-19 JP JP2018051046A patent/JP6620829B2/ja active Active
-
2019
- 2019-06-10 US US16/436,301 patent/US20200148753A1/en not_active Abandoned
- 2019-12-13 CY CY20191101311T patent/CY1122530T1/el unknown
-
2021
- 2021-12-01 US US17/539,926 patent/US20220340646A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR091218A1 (es) | Agente terapeutico o agente profilactico para los trastornos cognitivos | |
| MX371442B (es) | VARIANTE DE LA REGION FC ESPECIFICA PARA FCyRIIB. | |
| MX2018010733A (es) | Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas. | |
| PE20141672A1 (es) | FORMULACION PARA ANTICUERPO ANTI-alfa4�7 | |
| ES2691070T3 (es) | Péptidos antiinflamatorios y composición que comprende los mismos | |
| MX2020001450A (es) | Composiciones para reducir la inmunosupresion por celulas de tumor. | |
| BR112014013175A8 (pt) | composições de liberação prolongada baseadas em lipídios anfipáticos e processo para preparar comprimidos de composição de liberação prolongada | |
| MX2018012166A (es) | Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1). | |
| GT201200172A (es) | Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cáncer y enfermedades inmunes | |
| SA520412669B1 (ar) | تصنيع ذيفانات عصبية ناتجة عن معاودة الارتباط الجيني من المطثية الوشيقية | |
| PE20150200A1 (es) | Formulacion de anticuerpos | |
| ES2693321T3 (es) | Péptidos antiinflamatorios y composición que comprende los mismos | |
| AR090465A1 (es) | Formas solidas de un profarmaco de nucleotidos de tiofosforamidato | |
| BR112012018947B8 (pt) | anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica | |
| AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
| BR112015003591A8 (pt) | Usos de lys-c e métodos para fabricação de um polipeptídeo proteoliticamente processado | |
| BR112014002884A2 (pt) | composição para estimulação ovariana controlada | |
| UY36920A (es) | Formulaciones de aminoácidos de liberación modificada administradas por vía oral | |
| DOP2019000193A (es) | Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende | |
| AR092981A1 (es) | Biomarcadores predictivos de la respuesta clinica al acetato de glatiramero | |
| BR112015020904A2 (pt) | microrganismos e métodos para produção de butadieno e compostos relacionados por assimilação de formiato | |
| AR083126A1 (es) | Composicion vacunal para el control de las infestaciones por ectoparasitos | |
| CO7131387A2 (es) | Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido | |
| NI202000031A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
| BR112016013157A2 (pt) | peptídeos resistentes à protease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |